Global contract development and manufacturing organization Recipharm has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
The agreement was announced following the successful quality audit and will see Recipharm aseptically pack single-use vaccines used to treat a severe infectious disease that affects both young children and infants.
The containers will be filled using Recipharm’s specialist blow/fill/seal capabilities (b/f/s), creating products that are quick to distribute and simplifying administration for healthcare providers.
Recipharm plans to recruit over 30 members of staff between 2022 and 2026 as the product scales toward commercial production.
Yves Buelens, general manager at Recipharm’s facility in Kaysersberg, says, “We are very proud to be supporting a big pharma partner in the delivery of a vital vaccine to the market.
“This deal is indicative of Recipharm’s successful and ongoing product portfolio diversification. We’ve invested heavily into new capabilities that have built on our b/f/s/ expertise and, as a result, strengthened our biotech offering. We are now in a position to welcome new biopharma projects to the Kaysersberg site.”
Recipharm is investing almost 14 million euros into its vaccine manufacturing offering at the site.
Located in the Alsace region of France, Kaysersberg is one of Recipharm’s specialist sterile manufacturing facilities which had been previously dedicated to the exclusive production of sterile liquids for therapeutic areas, including eye care and ear drops.
The facility has been inspected and approved by multiple regulatory agencies across the globe including ANSM (EU-GMP), FDA, and Brazil’s ANVISA. It also holds a number of approvals for its environmental management systems and occupational health and safety management system.
